Avid Bioservices Inc (CDMO)

[Protector]

entdoc, you are wrong with that reasoning.

That assumes that the Bavi arm patients would at the same moment do whatever it was the Doce+Placebo patients did to achieve this out performance.

And if Bavi works, which it does, then that is impossible because the Bavi patients would take much longer to, for instance progress, and would therefore only do later what the Doce patients do now (for instance get a 3rd line treatment).

So we had the look-in into data of DEC 2015 §meeting IDMC JAN 2016, processing and letter to PPHM in FEB 2016). In DEC 2015 the trial was up 24 months and the hockey stick enrolment shows the patients bulk of the 154 patients (77 CTRL +77 BAVI) are only in the trial for about 15 to 18 months.

So you can see many CTRL patients outlive while you see the Bavi patients do the normal cycle. In he MOS table you do NOT see the Bavi patients that take a 3rd ln treatment (and hence will indeed perform and ALSO outperform THEIR trial design expectation) because they are STILL ALIVE. SO it is TOO SOON now.

That is why I posted that I don't understand that PPHM closed SUNRISE so easy because they know that TOO.